A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients With Bipolar I Disorder
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2015
At a glance
- Drugs ELND 005 (Primary) ; Lamotrigine; Valproic acid
- Indications Bipolar I disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Elan Pharma International
- 11 Oct 2015 Primary endpoint added, Trial focuses on the Adverse reactions also as per ClinicalTrials.gov.
- 07 Apr 2014 Status changed from recruiting to discontinued, as reported by a Transition Therapeutics media release.
- 05 Jan 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2012-001935-30).